A Permanent Cure For Type 1 Diabetes?
Type 1 diabetes is the most prevalent metabolic disorder among young people. Approximately two million Europeans suffer from the disease, and the group of patients grows by an average of 3% annually. The origins of the disease remain unknown, but an effective therapy with permanent results and without side effects may be found in the near future, according to Professor Chantal Mathieu of the Department of Clinical and Experimental Endocrinology. A new approach using active biopharmaceuticals appears promising. Type 1 diabetes is an auto-immune disorder by which the immune system of the patient attacks his/her own body. Insulin-producing beta cells in the pancreas are destroyed, deregulating the patient’s blood sugar levels and leading the patient to require regular insulin injections to survive. Moreover, complications such as eye diseases, kidney conditions and vascular diseases may drastically reduce life expectancy and quality of life. But new research may change this reality. The new therapy was developed by ActoGenix, a biopharmaceutical spin-off of Ghent University and the VIB. The spin-off specialises in the development and valorisation of ActoBiotics, a new class of orall Continue reading >>